Bastiaan Sallevelt

96 CHAPTER 2.2 Table SI1.3 STOPP - Clarity rating of conditions, from lowest to highest ranking. STOPP Condition Clarity rating n=80 K1 [falls] 0% K2 [falls] 0% K4 [falls] 0% A1 prescribed without an evidence-based clinical indication. 8% A2 prescribed beyond the recommended duration, where treatment duration is well defined 8% A3 [users with...duplicate drug class prescription] 17% L2 without concomitant laxative 17% L3 without short-acting opioids for break-through pain 17% M1 [users with…concomitant use of two or more drugs with antimuscarinic/anticholinergic properties] 17% B5 as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias 33% B6 as first-line treatment for hypertension 33% B13 in severe heart failure characterised by hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate therapy for angina 33% C3 with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding 33% C6 in patients with stable coronary, cerebrovascular or peripheral arterial disease 33% D1 with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, or prior history of urinary retention 33% D2 as first-line antidepressant treatment 33% D5 for ≥ 4 weeks 33% D8 in patients with delirium or dementia 33% D9 in patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other nonpharmacological treatments have failed 33% D10 as hypnotics, unless sleep disorder is due to psychosis or dementia 33% D14 [users of…first-generation antihistamines] 33% H2 with severe hypertension or severe heart failure 33% B4 with bradycardia (< 50/min) , type II heart block or complete heart block 42% G3 with a history of narrow angle glaucoma or bladder outflow obstruction 42% H7 with concurrent cardiovascular disease 42% I1 with dementia, or chronic cognitive impairment or narrow-angle glaucoma or chronic prostatism 42% B11 in patients with hyperkalaemia. 50%